Phase I/II Study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 9, 2008, Pages 1012-1017

  Atagi, Shinji ^a   Kawahara, Masaaki ^a   Kusunoki, Yoko ^a   Takada, Minoru ^a   Kawaguchi, Tomoya ^a   Okishio, Kyoiti ^a   Kubo, Akihito ^a   Uehira, Kazutaka ^a   Yumine, Katsuyuki ^a   Tomizawa, Yoshio ^b   Saito, Ryusei ^b   Fukai, Shimao ^c   Komatsu, Hikotaro ^d  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b National Nishi Gunma Hospital   (Japan)

^c National Hospital Organization Ibaraki Higashi National Hospital The Center of Chest Diseases and Severe Motor Intellectual Disabilities   (Japan)

^d National Hospital Organization   (Japan)

Author keywords

Docetaxel; Non small cell lung cancer; Phase I II; S 1; Second line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TAXOID; TEGAFUR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SKIN MANIFESTATION; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; ULCER; VOMITING; CANCER STAGING; DRUG COMBINATION; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TEGAFUR;

EID: 58149136462     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318183f8ed     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology American Society of Clinical Oncology treatment of unresect-able non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;15:330-353.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
4. Ohe Y, Ohashi Y, Kubota K, Tamura T, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-323.
5. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955-959.
6. Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
7. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-1237.
8. Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22(2 Suppl 4):22-29.
9. Gueritte-Voegelein F, Guenard D, Lavelle F, et al. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991;34:992-998.
10. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
11. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
12. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009.
13. Kawahara M, Furuse K, Segawa Y, et al. S-1 Cooperative Study Group (Lung Cancer Working Group). Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001;85:939-943.
14. Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-7864.
15. Wada Y, Yoshida K, Suzuki T, et al. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorou-racil in human gastric cancer cell lines. Int J Cancer 2006;119:783-791.
16. Suto A, Kubota T, Fukushima M, et al. Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice. Oncol Rep 2006;15:1517-1522.
17. National Cancer Institute: Common Toxicity Criteria (CTC) v2.0. http:// ctep.cancer.gov/reporting/ctc.html
18. Kaplan ES, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:557-580.
19. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer reviously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
20. Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small cell lung cancer. J Clin Oncol 2006;24:2800-2807.
21. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353: 123-132.
22. Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005;16:294-299.
23. Wachters FM, Groen HJ, Biesma B, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 2005;92:15-20.
24. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004; 91:482-488.
25. Takeda K, Negoro S, Tamura T, et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung ancer (NSCLC): results of a JCOG randomized trial (JCOG0104). Proc Am Soc Clin Oncol 2004;23:622.
26. Chou KT, Chen YM, Shih JF, et al. Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. Lung Cancer 2008;59: 64-68.
27. Kindwall-Keller T, Otterson GA, Young D, et al. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2005;11:1870-1876.
28. Chen YM, Perng RP, Tsai CM, et al. A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small cell lung cancer patients failing previous chemotherapy. Lung Cancer 2006;52:333-338.
29. Yoshida K, Hirabayashi N, Takiyama W, et al. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 2004;24:1843-1851.
30. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402-3407.
31. Yamaguchi K, Shimamura T, Hyodo I, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006;94:1803-1808.
32. DeSancho MT, Rand JH. Coagulopathic complications of cancer patients. In: Frei H, (Ed.), Cancer Medicine, BC Decker Inc., 2003. Pp. 2507-2516.